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116The development of genome-wide massively parallel
sequencing, ie, whole-genome and whole-exome
sequencing, and copy number approaches has raised high
expectations for the identiﬁcation of novel hereditary
colorectal cancer genes. Although relatively successful for
genes causing adenomatous polyposis syndromes, both
autosomal dominant and recessive, the identiﬁcation of
genes associated with hereditary non-polyposis colorectal
cancer has proven extremely challenging, mainly because
of the absence of major high-penetrance genes and the
difﬁculty in demonstrating the functional impact of the
identiﬁed variants and their causal association with tumor
development. Indeed, most, if not all, novel candidate non-
polyposis colorectal cancer genes identiﬁed so far lack
corroborative data in independent studies. Here we review
the novel hereditary colorectal cancer genes and syn-
dromes identiﬁed and the candidate genes proposed in
recent years as well as discuss the challenges we face.
Keywords: Cancer Predisposition; Hereditary Non-polyposis
Colorectal Cancer; Adenomatous Polyposis; Serrated Polypo-
sis; Mixed Polyposis.
Colorectal cancer (CRC) is the third most commoncancer in men (10.0% of all cancers) and the
second most common in women (9.2%) worldwide.1
Most CRCs arise as a consequence of somatic genomic
events that disrupt key cellular processes in individual
colonic epithelial cells. The vast majority of CRCs develop
from preexisting polyps; dysplasia is the true precursor
lesion. Therefore, removal of polyps results in decrease
of CRC incidence.2
Family history of cancer is one of the strongest pre-
dictors of CRC risk; this risk is higher with increasing
number of affected relatives and when CRC occurs at
young age.3 Crude estimates indicate that 20%–25% of
all CRC patients have at least 1 relative affected with the
disease, which may be explained by shared genetic and/
or environmental factors.4–6
It has been estimated that approximately 3%–6%of all
CRC patients carry germline mutations associated with
syndromic hereditary CRC. This genetic predisposition to
CRC has been classically associated with germline muta-
tions or epimutations in the DNA mismatch repair (MMR)
genes MLH1, MSH2, MSH6, and PMS2 for non-polyposis
cases and in APC and MUTYH (recessive inheritance) for
adenomatous colonic polyposis. Other CRC predisposingREV 5.4.0 DTD  YJCGH54936_proof  1syndromes, characterized by the presence of hamartom-
atous polyps, are caused bymutations in SMAD4, BMPR1A,
STK11, and PTEN (Figure 1).7 Despite this knowledge,
much of the genetic predisposition to CRC remains unex-
plained. This missing heritability may be in part multi-
factorial, ie, caused by the conjunction of moderate-risk or
low-risk genetic variants, possibly in conjunction with
environmental or lifestyle risk factors.8 It has been esti-
mated that CRC low-penetrance variants, including the
ones that have not been yet identiﬁed, may explain atmost
5%–10% of the heritability to CRC.9 Recently, a model
created to accurately determine the risk for CRC on the
basis of common genetic CRC susceptibility loci showed
that the accumulation of risk variants is signiﬁcantly
associated with increased risk of CRC in individuals with a
family history of CRC.10
The identiﬁcation of a bona ﬁde germline pathogenic
mutation that causes the increased risk and aggregation
of CRC in a family has clear consequences in the clinical
management of its members11; therefore, important
efforts are being invested to identify novel genes that
explain this predisposition, in particular in families with
clear dominant inheritance of the disease. Here we aim to
provide a review of the latest advances and discuss
current challenges and future perspectives in this ﬁeld.Current Approaches for the
Identiﬁcation of Novel Hereditary
Colorectal Cancer Genes
Before the development of high-throughput sequence
capture methods and next-generation sequencing tech-
nologies, hereditary cancer studies were mainly based on
genome-wide linkage analysis of large individual pedigrees
or multiple pedigrees, followed by positional cloning and4 November 2016  7:37 pm  ce CLR
Figure 1. Clinical classiﬁcation of hereditary CRC and polyposis syndromes and causal genes (current diagnostic value).
*biallelic MMR, biallelic inactivation of DNA MMR genes (MSH2, MSH6, MLH1, PMS2, and MSH3).
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232study of somatic analysis of mutations, which led to the
identiﬁcation of the previously mentioned hereditary CRC
genes.12–14 However, despite the enormous efforts made
after the identiﬁcation of the most prominent hereditary
CRC genes, linkage analyses followed by positional cloning
and/or sequencing of the genes (coding regions) located
within the candidate linkage peaks seemed to be unable to
identify additional causal genes,15–27 implying large het-
erogeneity, oligogenic or polygenicmodes of inheritance, or
unconventional mechanisms of gene inactivation among
other possibilities.
In the last decade, the rapid development of
massively parallel sequencing–based approaches and
genome-wide copy number techniques, associated with
the decrease in their economic cost, restored hope for
the identiﬁcation of additional hereditary cancer genes.
Among the approaches most commonly used for the
identiﬁcation of causal mutations in a genome-wide
manner are whole-genome sequencing (WGS) and
whole-exome sequencing (WES) and genome-wide, usu-
ally array-based, scanning of copy number alterations.
These approaches are performed in isolated high-risk
families (large pedigrees) or in multiple families or
probands (often with an early age of cancer onset as an
indicator of genetic predisposition) to identify a shared
causal gene. Moreover, in some instances, combination of
the above-mentioned methodologies, such as WES/WGS
and linkage data, and/or combination of germline and
somatic analyses are used to optimize the process.
Novel Hereditary Colorectal Cancer Genes
By using the above-mentioned approaches several
novel genes have been proposed as responsible for he-
reditary CRC cases, in some instances also associated
with polyposis. For some of the identiﬁed genes, the
evidence gathered to date is robust, and their testing has
been included in routine genetic diagnostics, whereas for
others, the identiﬁcation of additional pathogenicREV 5.4.0 DTD  YJCGH54936_proof  1mutations in high-risk families is mandatory to provide
the required evidence to consider the study of the gene
in the clinical setting.
Genes Identiﬁed Through Agnostic Approaches
Novel hereditary colorectal cancer genes. POLE and
POLD1: polymerase proofreading-associated polyposis. By
using a combination of WGS/WES and linkage analysis in
probands with more than 10 adenomas by age 60 but no
germline mutations in APC, MUTYH, or the MMR genes,
Palles et al28 identiﬁed mutations in the proofreading
(exonuclease) domains of DNA polymerase epsilon
(POLE; MIM# 174762) and delta (POLD1; MIM# 174761)
in individuals/families with multiple colorectal ade-
nomas and CRC, observing high risk of endometrial
cancer in female POLD1 mutation carriers. The study of
additional series of familial CRC and/or polyposis cases
has provided conclusive evidence of the causal role of
germline polymerase-proofreading mutations in the
predisposition to CRC and polyposis, allowing a better
deﬁnition of the syndrome and of its associated
phenotype.29–37
Data gathered point to a highly penetrant autosomal
syndrome characterized by attenuated or oligo-
adenomatous colorectal polyposis, CRC, gastroduodenal
(mostly duodenal) adenomas, and probably brain
tumors. Moreover, female POLD1mutation carriers are at
very high risk of endometrial cancer and possibly at
moderate risk of breast tumors.28,29,31,32,35 The presence
of other tumor types has also been reported in some
families,28,30,32,33,37 ﬁtting with a defect in a mecha-
nism of correction of DNA errors. The polymerase-
proofreading–associated phenotype may appear as non-
polyposis CRC syndrome,29,35 and in some instances,
presence of mismatch repair defects in the tumors has
been reported.31,34
Tumors developed in the context of polymerase-
proofreading mutations, both germline and somatic,4 November 2016  7:37 pm  ce CLR
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348show a hypermutated phenotype, leading to more than a
million base substitutions in some tumors, with a tumor
mutational spectrum characterized by increased pro-
portion of G:C to T:A and A:T to C:G transversions.38,39
Similar to microsatellite instability (MSI), the pres-
ence of somatic mutations in POLE has been recently
associated with favorable prognosis in sporadic tu-
mors,40 but whether this also applies to tumors arising in
germline mutation carriers remains unsolved.
NTHL1-associated adenomatous polyposis. By per-
forming WES in 51 adenomatous polyposis and CRC
patients from 48 families, Weren et al41 identiﬁed 3
Dutch families with homozygous truncating mutations in
the NTHL1 gene (MIM# 616415), ﬁtting with a recessive
disorder. All 3 families carried the same NTHL1 mutation
in homozygosis, c.268C>T (p.Gln90*).
Like MUTYH, a known recessive adenomatous pol-
yposis gene, NTHL1 encodes a glycosylase involved in
base excision repair, the primary pathway for the repair
of oxidative DNA damage. In comparison with the
MUTYH protein, NTHL1 targets a broader range of DNA
lesions,42 and the tumors developed by NTHL1 mutation
carriers show an increase in C:G>T:A transitions rather
than C:G>A:T transversions,41 as has been observed in
double knockout mice.43
Despite the recent description of the syndrome and
the publication of only 4 families carrying biallelic
NTHL1 mutations, the NTHL1-associated phenotype may
be not only characterized by the presence of attenuated
adenomatous polyposis and CRC but represents a multi-
tumor syndrome41,44 whose precise tumor spectrum
remains to be deﬁned.
GREM1: mixed polyposis in Ashkenazi Jewish fami-
lies. Hereditary mixed polyposis syndrome (MIM#
601228) is an unusual disease associated with polyps of
multiple and mixed morphologies, including serrated
lesions, Peutz-Jeghers polyps, juvenile polyps, conven-
tional adenomas, and CRC, in the absence of any identi-
ﬁable extracolonic features.45 Between 1999 and 2008
linkage analyses performed in Ashkenazi families with
hereditary mixed polyposis allowed to map a mixed
polyposis gene (also known as CRAC1) to chromosome
15q13.3 and to identify a shared haplotype within the
region, suggesting a single founder mutation.46–48 How-
ever, no novel, potentially pathogenic mutations in the
genes located in the region were identiﬁed. The use of a
custom oligonucleotide array to search for copy number
variation in the region identiﬁed the presence of a het-
erozygous single-copy duplication of about 40 kilobases
(kb) centered on chr15:30.77 Mb present in the affected
members of the studied families. The change was a
simple tandem tail-head duplication with the insertion of
a 30 base pair sequence of unknown origin and no
homology to known sequences between the duplicons.
The duplication extended from intron 2 of SCG5 to a
site just upstream of the GREM1 CpG island and is
associated with greatly increased, allele-speciﬁc GREM1
expression.49REV 5.4.0 DTD  YJCGH54936_proof  1To date, the GREM1 40-kb upstream duplication has
only been found in the Ashkenazi Jewish descendants of
a single founder. However, the phenotype is not
restricted to mixed polyposis, which has led to recom-
mend genetic testing of the GREM1 founder duplication
to all Ashkenazi Jewish subjects with multiple colorectal
polyps and those fulﬁlling the criteria for non-polyposis
CRC.50
Recently, a disease-causing tandem-repeat duplica-
tion of 16 kb in the regulatory region of GREM1 (7.7 kb
upstream of the gene) was identiﬁed in a non-Ashkenazi
family with attenuated polyposis with some indications
of polyp morphology similar to a juvenile and a meta-
plastic type.36 Likewise, a duplication of the whole
GREM1 gene was identiﬁed in a single early-onset CRC
patient without features of mixed polyposis.51 Moreover,
it has been demonstrated that a common GREM1 variant
affecting an enhancer, rs16969681, is also associated
with CRC susceptibility, conferring approximately 20%
differential risk in the general population.52
RNF43-associated serrated polyposis. Serrated polyp-
osis is a clinically deﬁned syndrome with multiple
serrated polyps in the colorectum and increased CRC
risk. The true prevalence of serrated polyposis syndrome
(SPS), as deﬁned by the World Health Organization
(WHO) criteria, is unclear because of the risk of bias
across studies, but it is likely to be below 0.09% as
derived from primary colonoscopy screening pro-
grams.53 Moreover, the risk to develop CRC (approxi-
mately 1.9% in 5 years), lower than it had been ﬁrst
estimated, largely depends on presence of serrated
polyps containing dysplasia, advanced adenomas, and/or
combined WHO criteria 1 and 3.54,55
For years, researchers have unsuccessfully tried to
identify the genetic cause(s) of this clinical entity by
agnostic approaches or studying genes that cause other
colonic polyposis syndromes.56 By carrying out WES in
20 unrelated subjects with multiple sessile serrated ad-
enomas (16 fulﬁlled the WHO criteria of SPS), Gala et al57
identiﬁed germline mutations in genes that regulate
senescence, ATM, PIF1, TELO2, XAF1, and RBL1, in 5
patients and nonsense mutations in RNF43, a regulator of
ATM/ATR DNA damage response, in 2 of the 20 studied
patients (ages at diagnosis, 51 and 52). The protein
encoded by RNF43 is a RING-type E3 ubiquiting ligase,
which is thought to negatively regulate Wnt signaling.58
Knockout of this gene had been demonstrated to
contribute to an intestinal polyposis phenotype in
mice.59 Subsequently, WES performed in a serrated
polyposis family, including 2 affected and 2 non-affected
individuals, revealed a stop-gain novel mutation in
RNF43 shared by the affected family members and ab-
sent in the healthy ones.60 Recently, another WES project
involving 4 families (6 individuals) with serrated pol-
yposis identiﬁed a splice-site mutation in RNF43 that
resulted in a truncating protein product.61 The mutation
was identiﬁed in 3 siblings in the family, 2 with serrated
polyposis diagnosed at age 65 (number of polyps >100,4 November 2016  7:37 pm  ce CLR
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464predominantly sessile serrated adenomas) and at age 64
(number of polyps >20 sessile serrated adenomas or
hyperplastic polyps) and the third with rectal cancer and
a hyperplastic polyp at age 49. Two children of the latter
subject, also carriers of the RNF43 mutation, showed
several sessile serrated adenomas or hyperplastic polyps
at colonoscopy examination at 35 and 37 years. Four
additional family members screened for the mutation
resulted in non-carriers, and all had normal colonos-
copies. A total of 16 serrated polyps, 5 adenomas, and 1
tumor from the 5 identiﬁed mutation carriers could be
analyzed, all showing somatic inactivation of the wild-
type allele, thus conﬁrming the tumor suppressor
nature of RNF43.61
In total, germline RNF43 mutations have been iden-
tiﬁed in 12.5% (2/16)57 and 25% (1/4)61 of unrelated
patients satisfying the WHO criteria of SPS, thus sup-
porting the need to include mutation screening of RNF43
in routine germline testing, which is something that has
not yet been done because of the recent (2016) publi-
cation of the second and conclusive study. Interestingly,
in vitro and preclinical evidence has shown that RNF43
mutant tumors are sensitive to Wnt secretion inhib-
itors,62–64 opening a potent therapeutic window for
RNF43 mutation carriers.
Novel candidate genes. In addition to the genes
mentioned above, additional candidates have been pro-
posed with more or less compelling evidence of causality
for hereditary CRC (Table 1). Among the genes with
strongest evidence of association with hereditary CRC
are FAN1,65 RPS20,66 PTPN12,67 LRP6,67 BUB1 and
BUB3,68 FOCAD,69 and the constitutional epigenetic
silencing of PTPRJ.70 FAN1, BUB1, and BUB3 are involved
in DNA damage response and genetic instability, and
LRP6 is a component of the Wnt-Fzd-LRP5-LRP6 com-
plex that triggers b-catenin signaling. RPS20 encodes a
ribosomal protein, FOCAD, a focal adhesion protein, and
PTPN12 and PTPRJ, protein tyrosine phosphatases
(GeneCards; www.genecards.org). In addition to these
genes, the study of relatively large numbers of families/
probands has allowed the identiﬁcation of several
candidate genes71–78; however, additional evidence
needs to be gathered to discard or conﬁrm their causal
role in CRC predisposition. For the SEMA4A gene, ﬁrst
described as a strong candidate for hereditary non-
polyposis CRC,79 a subsequent study failed to validate
the variation in SEMA4A as a determinant of CRC risk.80
In conclusion, the conﬁrmation of the diagnostic value of
all these candidate genes depends on the publication of
additional supporting and conclusive evidence.
Genes Identiﬁed Through Candidate
Gene Approaches
The implication of known hereditary CRC genes in
DNA repair processes or in well-known relevant path-
ways for colorectal carcinogenesis has motivated
researchers to assess the causal role of genes related toREV 5.4.0 DTD  YJCGH54936_proof  1these mechanisms and pathways in CRC predisposition.
In the case of AXIN2, a component of the Wnt pathway,
there is convincing evidence of its pathogenicity for
attenuated familial adenomatous polyposis with or
without features of ectodermal dysplasia.81–83
Despite the efforts made to elucidate their causal role,
the evidence gathered to date is still insufﬁcient or
contradictory to include OGG1,84–86 NUDT1,84,85 BMP4,87
and EPHB88 in routine genetic diagnostics. On the other
hand, AMER1, UNC5C, and GALNT12 have been discarded
as high-penetrance genes, although a role as a moderate-
risk/low-risk gene cannot be ruled out.89–93
Germline and Somatic Biallelic
Inactivation of DNA Mismatch
Repair Genes
The clinical spectrum linked to germline variation in
the MMR genes, initially restricted to monoallelic muta-
tions in Lynch syndrome, keeps expanding. Constitu-
tional mismatch repair deﬁciency (CMMRD) is a distinct
childhood cancer predisposition syndrome characterized
by the presence of homozygous or biallelic germline
mutations in the MMR genes. Phenotypically, biallelic
carriers may develop hematologic malignancies, brain
tumors, and gastrointestinal cancers as well as café-au-
lait spots and other ﬁndings that mimic neuroﬁbroma-
tosis type 1.94–96 In 2014, the CMMRD consortium
reported the genetic and clinical characteristics of a
series of 23 children with CMMRD from 14 families; 18
children from 13 families were genetically characterized,
showing the universal presence of café-au-lait spots and
the extremely high penetrance of cancer because 22 of
the 23 CMMRD children had developed tumors (4
of them gastrointestinal cancer). Of note, the presence of
gastrointestinal polyposis was reported in half of the
described carriers (9/18) (ages at diagnosis, 9–17.5
years), a clinical trait that had already been observed.95
Several observations suggest that only less penetrant
(mild) MMR gene mutations are viable in homozygosis,
whereas the highly penetrant, such as those causing Lynch
syndrome, are embryonic lethal when they occur in the 2
alleles: (1) the scarcity of Lynch syndrome–related can-
cers in the parents and other relatives of biallelic mutation
carriers; (2) the fact that many germline mutations re-
ported in CMMRD have not been reported in Lynch syn-
drome; and (3) MSH2 mutations, the most commonly
reported and highly penetrant in Lynch syndrome, are the
least common in CMMRD.95–97
Very recently, WES was carried out in 102 unrelated
patients with adenomatous polyposis in absence of
germline mutations in the classic and novel polyposis
genes, which allowed the identiﬁcation of 1 case with
biallelic PMS2 mutations and 2 cases with biallelic mu-
tations in MSH3, another DNA MMR gene, following an
autosomal recessive mode of inheritance.98 All 4 MSH3
mutations were deleterious variants (c.1148delA,4 November 2016  7:37 pm  ce CLR
Table 1. Novel Genes and Candidate Genes of CRC Predisposition Identiﬁed Through WES/WGS or Genome-wide
CN Approaches
Gene Phenotype Original study Additional evidence
Polyposis
POLEa POLD1a Adenomatous polyposis, CRC,
endometrial cancer/non-
polyposis CRC
Palles et al, 201328 Valle et al, 201429
Rohlin et al, 201430
Elsayed et al, 201531
Spier et al, 201532
Hansen et al, 201537
Jansen et al, 201534
Aoude et al, 201533
Rohlin et al, 201636
Bellido et al, 201635
NTHL1a (recessive) Adenomatous polyposis, CRC,
multiple tumors
Weren et al, 201541 Rivera et al, 201544
MSH3a (recessive) Adenomatous polyposis, benign
and malignant tumors (adult
CMMRDQ10 )
Adam et al, 201698 Wimmer et al, 200895
Bakry et al 201496
(gastrointestinal
polyposis in CMMRD
caused by PMS2,
MSH6, MLH1, and
MSH2 mutations)
GREM1a Mixed polyposis of serrated and
juvenile types
Jaeger et al, 201249 (Ashkenazi
founder 40-kb duplication)
Venkatachalam et al,
201151
Laitman et al, 201550
Rohlin et al, 201636
RNF43,a ATM, PIF1, TELO2,
XAF1, RBL1
Serrated polyposis Gala et al, 201457 Taupin et al, 201560
(RNF43)
Yan et al, 201661 (RNF43)
FOCAD Polyposis Weren et al, 201569
MCM9 Mixed polyposis, CRC, primary
ovarian failure
Goldberg et al, 2015113
DSC2, PIEZO1, ZSWIM7 Adenomatous polyposis Spier et al, 201677
Non-polyposis CRC
RSP20 Hereditary non-polyposis CRC Nieminen et al, 201466
FAN1 Hereditary non-polyposis CRC Segui et al, 201565 Smith et al, 2016114
(hereditary pancreatic
cancer)
BUB1, BUB3 Early-onset and familial CRC de Voer et al, 201368
SEMA4A Hereditary non-polyposis CRC Schulz et al, 201479 Kinnersley et al, 201680 (no
validation)
PTPRJ (epimutation) Early-onset CRC Venkatachalam et al, 201070
PTPN12, LRP6 Early-onset CRC de Voer et al, 201667
POLE2, POT1, MRE11,
IL12RB1, LIMK2
Early-onset CRC Chubb et al, 201678 Spier et al, 201532 (POLE2)
ROBO1 Hereditary breast/ovarian cancer,
early-onset CRC
Villacis et al, 2016115
HNRNPA0, WIF1 CRC, multiple tumors Wei et al, 2015116
UACA, SFXN4, TWSG1, PSPH,
NUDT7, ZNF490, PRSS37,
CCDC18, PRADC1, MRPL3,
AKR1C4
Hereditary non-polyposis CRC Gylfe et al, 201373
CDKN1B, XRCC4, EPHX1,
NFKBIZ, SMARCA4,
BARD1
Hereditary non-polyposis CRC Esteban-Jurado et al, 201471
ADAMTS4, CYTL1, SYNE1,
MCTP2, ARHGAP12, ATM,
DONSON, ROS1, MCTP2
Early-onset and familial CRC Tanskanen et al, 201575
BRCA2/FANCD1, BRIP1/
FANCJ, FANCC, FANCE,
REV3L/POLZ
Hereditary non-polyposis CRC Esteban-Jurado et al, 201676 Garre et al, 2015107
(BRCA2)
Yurgelun et al, 2015108
(BRCA2, BRIP1)
REV 5.4.0 DTD  YJCGH54936_proof  14 November 2016  7:37 pm  ce CLR
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Table 1. Continued
Gene Phenotype Original study Additional evidence
ZRANB1, CDC27, CENPE,
DDX12, HAUS6/FAM29A,
HIST1H2BE, KIF23, TACC2,
ZC3HC1, CTBP2, IRF5,
MED12, RNF111, SF1,
TLE1, TLE4, TRIP4, BTNL2,
BAGE, CARD8, FANK1,
KIR2DL1, KIR2DS4,
KIR3DL3, MASP1, NLRP8
Hereditary non-polyposis CRC DeRycke et al, 201372 —
FANCM, LAMB4, PTCHD3,
LAMC3, TREX, NOTCH3
CRC Smith et al, 201374
aCurrent diagnostic value.
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695c.2319-1G>A, c.2760delC, and c.3001-2A>C), and the
tumors of the affected carriers showed high MSI of
dinucleotides and tetranucleotides and complete loss of
the MSH3 protein. In total, 4 MSH3 biallelic carriers were
identiﬁed, showing an associated phenotype character-
ized by the presence of colorectal adenomatous polypo-
sis, diagnosed in their 30s in most cases, accompanied by
additional benign and malignant lesions in the gastroin-
testinal tract and extracolonic, such as duodenal
adenomas (2/4 biallelic carriers), thyroid adenomas
(2/4), intraductal papillomas (2/4), gastric cancer (1/4),
and astrocytoma (1/4).98 The phenotype observed in
MSH3 biallelic carriers largely resembles that of attenu-
ated familial adenomatous polyposis, although still
conserving some features of CMMRD occurring at more
advanced age (not in childhood), most probably because
MSH3 mutations in heterozygosity, unlike the Lynch
syndrome–associated MMR genes, are not considered as
disease causing.
In as many as 60%–70% of cases in which Lynch
syndrome is clinically and molecularly suspected
because of the presence of MMR deﬁciency in the tumors,
genetic testing fails to identify a germline MMR gene
mutation.99 These cases have been grouped as Lynch-
like. Unlike sporadic microsatellite unstable CRCs,
Lynch-like CRCs do not show epigenetic inactivation of
the DNA MMR gene MLH1 or mutation in BRAF. We
currently know that for 50%–60% of the so-called
Lynch-like cases, the MMR deﬁciency detected in the
tumors may be explained by the presence of double so-
matic hits in MMR genes,100–103 most probably repre-
senting sporadic cases. Also, germline mutations in other
genes that cause impaired DNA error correction, such as
MUTYH or the proofreading domains of POLE and POLD1,
may in some instances cause MMR deﬁciency in the
tumors because of the somatic alteration of MMR
genes.31,34,104–106 Taking into account the presupposed
heterogeneity of the so-called Lynch-like entity, in
absence of a known germline defect, genetic counseling
and clinical surveillance should be guided by the family
and/or individual cancer history.REV 5.4.0 DTD  YJCGH54936_proof  1Overlap Among Hereditary
Cancer Syndromes
The identiﬁcation of novel hereditary CRC genes has
centralized the research in the ﬁeld during the last
decade. However, the prevalence of pathogenic muta-
tions in the novel genes identiﬁed is very small; it is
almost insigniﬁcant when considering the entire burden
of unexplained hereditary cases. The use of next-
generation sequencing-based approaches, either for the
discovery of novel genes (WGS or WES) or for genetic
testing (WES or multi-gene panels), has allowed the
identiﬁcation of hereditary CRC families with germline
pathogenic mutations in genes classically associated with
other cancer syndromes such as BRCA1 and
BRCA2,76,107,108 TP53,109 BARD1,71 or BRIP176,108 or
associated with other very distinct CRC/polyposis syn-
dromes. This has been the case for the adenomatous
polyposis genes MUTYH and POLD1 and the juvenile
polyposis gene BMPR1A, which have been found mutated
in hereditary non-polyposis CRC fam-
ilies.29,35,104,106,110,111 These observations support the
use of generic gene panels in routine genetic diagnostics
of hereditary cancer. Moreover, a broad coverage of
genes would also identify clinically misdiagnosed cases,
eg, misdiagnosed polyposis types. Nevertheless, the
infrequency of these out-of-the-rule exceptions suggests
that clinical phenotypes are the best way to prioritize,
mainly when coping with variants of unknown
signiﬁcance.
More Than 1000 Exomes of Familial and
Early-onset Colorectal Cancer Patients
Attempts have been made to estimate by using
agnostic approaches the fraction of CRC cases in which
the molecular basis of predisposition can be identiﬁed.
Recently, Chubb et al78 comprehensively assayed the
impact of rare (MAF <1%) germline mutations on CRC
risk by analyzing WES data from 1006 early-onset4 November 2016  7:37 pm  ce CLR
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781unrelated CRC patients (<55 years old at diagnosis) with
at least 1 ﬁrst-degree relative affected with CRC and
1609 healthy controls. In total, 9% of the analyzed
patients carried disruptive (nonsense, frameshift)
mutations in the already known high-penetrance genes,
showing a signiﬁcant enrichment for mutations affecting
MSH2, MLH1, and APC. When considering all rare non-
synonymous variants, only 31% of familial CRC cases
could be explained by already known hereditary CRC
genes. Interestingly, for other well-documented CRC
genes including MSH6 and PMS2, no signiﬁcant associa-
tion was detected, reﬂecting a more limited contribution
to CRC predisposition.
When searching for novel CRC predisposing genes,
the analysis was restricted to disruptive (nonsense and
frameshift) variants in genes recurrently mutated with
biological plausibility. This approach identiﬁed IL12RB1,
LIMK2, and POLE2 as novel potential candidates. A sub-
sequent analysis considering shared biological processes
revealed that the DNA-dependent DNA replication gene
set (Gene Ontology: genes involved in DNA replication
driven by DNA polymerases) was signiﬁcantly associated
with CRC, driven by disruptive mutations in the MMR
genes, but also in POLE2, POT1, andMRE11A. Overall, this
study conﬁrms the lack of further major high-penetrance
susceptibility genes that individually account for >1% of
the familial risk.782
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812Concluding Remarks
The application of genome-wide WES, WGS, and CN
approaches for the identiﬁcation of novel hereditary CRC
genes has been reasonably successful for polyposis
syndromes either dominant (POLE, POLD1, GREM1, and
RNF43) or recessive (NTHL1 and MSH3), although there
is still a high proportion of polyposes that are not
explained by currently known genes. Because POLE,
POLD1, and GREM1 mutation screening is already
implemented in routine genetic testing and/or multi-
gene panels, the study of NTHL1, MSH3, and RNF43 will
soon become available. Moreover, genetic counseling and
surveillance recommendations for mutation carriers of
these newly described genes/syndromes, currently
guided by the available clinical phenotypic observations,
will be reﬁned with the description and report of addi-
tional mutation carriers.
In the case of hereditary non-polyposis CRC, the
absence of novel major genes and the anticipated
extreme genetic heterogeneity are the major conclusions
derived from the research carried out so far. Despite the
enormous efforts made in recent years, the yield of
WES/WGS for the identiﬁcation of novel hereditary
non-polyposis CRC genes has been low. Moreover, none
of the proposed candidates has yet gathered the required
evidence and supporting validation to be included in
routine genetic diagnostics, an issue on which future/
current research should invest efforts and resources.REV 5.4.0 DTD  YJCGH54936_proof  1Adding to these complex circumstances is the inter-
pretation of the identiﬁed genetic variants, which hinders
the identiﬁcation and validation of novel genes. First, the
human genome harbors many rare variants, most of
which may not be clearly associated with a disease
phenotype, and second, some of these variants may
interplay with other genetic and/or environmental fac-
tors, which may in turn determine their expressivity.
The breakthroughs made through the years in the
identiﬁcation of novel CRC/polyposis predisposing genes
or candidate genes have made evident the relevance of
genes involved in DNA repair, DNA replication, and
maintenance of genomic instability. Furthermore, the
study of certain ethnicities such as Ashkenazi Jewish or
speciﬁc populations (eg, Finnish or Dutch) continues to
be helpful in the identiﬁcation of novel genes because of
the presence of either founder mutations, as was the case
for GREM1,49 or homozygous carriers of pathogenic
mutations, as happened with NTHL1.41 These ﬁndings
highlight the importance of combining regional or na-
tional studies with data sharing and coordination in in-
ternational consortia.
The presence of overlapping phenotypes, ie, causal
germline mutations in genes that mainly cause predis-
position to other tumor types or other phenotypes, has
been recurrently reported in recent years, especially
with the introduction of generic gene panels for genetic
testing in hereditary cancer or the use of WES/WGS for
research or diagnostic purposes. Although a priori this
phenomenon does not seem to be extremely frequent,108
it might well explain more uncharacterized familial cases
than the novel hereditary CRC gene candidates that are
identiﬁed so far. The study of additional series together
with genotyping of population-based cohorts will pro-
vide a more reﬁned assessment of the clinical spectrum
and expressivity of the germline variation detected.
Although historically only associated with hereditary
non-polyposis CRC (restricted to heterozygous mutations
in MSH2, MLH1, MSH6, and PMS2), through the years the
clinical and molecular spectra of pathogenic MMR gene
mutations have evolved to (1) CMMRD caused by
germline biallelic mutations96; (2) attenuated adenoma-
tous polyposis in the presence of germline biallelic mu-
tations, including in MSH3,98 an MMR gene with no effect
in heterozygosity; and (3) Lynch-like syndrome when
somatically inactivated (2 somatic hits).100–103
The possibility of oligogenic or polygenic inheritance
is no longer a theoretical hypothesis but a reality
exempliﬁed at one end by the presence of germline
pathogenic mutations in more than 1 high-penetrance
cancer-predisposing gene, the so-called multilocus
inherited neoplasia alleles syndrome,112 and at the other
end by the increased cancer risk in carriers of multiple
low-penetrance alleles. However, these extreme cases
most likely only represent the tip of the iceberg, because
the identiﬁcation and classiﬁcation of variants/genes of
moderate/lower expressivity, which probably exert their
effect when co-inherited with others or under speciﬁc4 November 2016  7:37 pm  ce CLR
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880environmental conditions, are one of the most difﬁcult
challenges we face in the ﬁeld.
Indeed, the oligogenic or polygenic inheritance,
together with the presence of alterations, genetic or
epigenetic, in non-coding regulatory regions (expression
or splicing regulators, or non-coding RNAs), opens the
door to additional studies in the numerous families
where neither WES nor WGS focused on variants of
evident functional impact has been able to identify a
monogenic cause for the familial aggregation of CRC.881
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